NANOBIOTIX Archives | Be Korea-savvy
Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval

Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval

Paris, France, and Cambridge, Massachusetts (USA) Apr. 4 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that Hensify® (NBTXR3) has obtained a CE mark for the treatment of locally-advanced soft tissue sarcoma (“STS”).  Hensify® is the brand name for NBTXR3 [...]

Combination of First-in-class NBTXR3, Radiotherapy, and Anti-PD-1 Immunotherapy Demonstrate Efficacy in Treating Resistant Pre-clinical in vivo Models of Lung Cancer

Combination of First-in-class NBTXR3, Radiotherapy, and Anti-PD-1 Immunotherapy Demonstrate Efficacy in Treating Resistant Pre-clinical in vivo Models of Lung Cancer

Paris, France; Cambridge, Massachusetts (USA); Apr. 2 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the ‘‘Company’’) a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced preclinical data from studies currently being conducted under its collaborations with The University of Texas MD Anderson Cancer Center and the Weill Cornell [...]

Nanobiotix Announces its Clinical Registration Plan in Head and Neck Cancers for the United States Following FDA Feedback

Nanobiotix Announces its Clinical Registration Plan in Head and Neck Cancers for the United States Following FDA Feedback

Paris, France; Cambridge, Massachusetts (USA); Mar. 26 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the Company has clarity on its regulatory pathway in the treatment of Head and Neck cancers for first-in-class radioenhancer NBTXR3. The [...]

Nanobiotix 2018 Annual Results

Nanobiotix 2018 Annual Results

Paris, France and Cambridge, Massachusetts, USA, Mar. 15 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited1 consolidated results for the fiscal year ended December 31, 2018: Major milestones achieved during the year: Positive Phase II/III [...]

Nanobiotix Receives €14 Million Through the Second Tranche Disbursement of Financing from the European Investment Bank

Nanobiotix Receives €14 Million Through the Second Tranche Disbursement of Financing from the European Investment Bank

Paris, France and Cambridge, Massachusetts (USA), Mar. 4 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the Company received €14 million through the second tranche disbursement of the non-dilutive loan from the European Investment Bank (EIB), which was originally [...]

Nanobiotix Plans to Conduct Registered Public Offering in the United States

Nanobiotix Plans to Conduct Registered Public Offering in the United States

Paris, France and Cambridge, Massachusetts, Jan. 16 (Korea Bizwire) – NANOBIOTIX SA (Euronext : NANO – ISIN : FR0011341205) announced today that it plans to conduct a registered public offering of its ordinary shares, including in the form of American Depositary Shares (ADSs) in the United States, and has confidentially submitted a draft registration statement [...]

Nanobiotix and MD Anderson Cancer Center Announce a Large-scale, Comprehensive Clinical Collaboration on NBTXR3

Nanobiotix and MD Anderson Cancer Center Announce a Large-scale, Comprehensive Clinical Collaboration on NBTXR3

Paris, France, Cambridge, Massachusetts (USA) and Houston, Texas (USA), Jan. 7 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205) and The University of Texas MD Anderson Cancer Center today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. [...]

Nanobiotix Revenues for the 3rd Quarter of 2018

Nanobiotix Revenues for the 3rd Quarter of 2018

Paris, France and Cambridge, Massachusetts, USA, Nov. 15 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its unaudited revenues for the third quarter of 2018. Income Statement for the third quarter of 2018 In € Q3 2018 Q2 2018 [...]

NANOBIOTIX: Positive Phase II/III Results for NBTXR3 in Soft Tissue Sarcoma Presented at ESMO

NANOBIOTIX: Positive Phase II/III Results for NBTXR3 in Soft Tissue Sarcoma Presented at ESMO

Paris, France, and Cambridge, Massachusetts (USA), Oct. 19 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, presented NBTXR3 positive Phase II/III Act.in.sarc results in patients with locally advanced Soft Tissue Sarcoma at the European Society for Medical Oncology (ESMO) 2018 Congress [...]

Nanobiotix Receives First Tranche Disbursement of 16 Million Euros Financing from European Investment Bank

Nanobiotix Receives First Tranche Disbursement of 16 Million Euros Financing from European Investment Bank

Paris, France and Cambridge, Massachusetts, Oct. 16 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company received an initial 16 million euros as the first disbursement under the previously announced non-dilutive loan from the European Investment Bank [...]